{
  "pmcid": "PMC12036300",
  "pmid": "40295977",
  "title": "The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease",
  "overall_score": 0.3228672980020444,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 14,
        "items": [
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*10",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*10",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*22",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*22",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*26",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*26",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*33",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*33",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Among 41 followed Syrian CAD patients on a doubled maintenance dose of clopidogrel (150 mg/day) after PCI, carriers of the CYP2C19*2 allele had similar rates of refractory angina symptoms (33.33% vs 38.89%, P > 0.9999) and MACE (16.67% vs 2.86%, P = 0.2744) compared with non-carriers; authors repeatedly conclude that no association was found between CYP2C19*2 and recurrent ischemic events with this dosing strategy.",
              "Sentence": "Genotypes carrying the CYP2C19*2 allele are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*1 + non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, CYP2C19*10, CYP2C19*22, CYP2C19*26, CYP2C19*33",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Table 5 shows that CYP2C19*2 carriers (n=6) had 33.33% refractory angina and 16.67% MACE, while non-carriers (n=35) had 38.89% refractory angina and 2.86% MACE; P > 0.9999 for refractory angina and P = 0.2744 for MACE, indicating no statistically significant association of CYP2C19*2 with recurrent ischemic events under a 150 mg/day maintenance dose.",
              "Sentence": "Genotypes CYP2C19*1/*2 + CYP2C19*2/*2 are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The allele frequencies were 8% for CYP2C19*2, 0% for CYP2C19*3, and 17% for CYP2C19*17. ... No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Table 5 shows that CYP2C19*2 carriers (n=6) had 33.33% refractory angina and 16.67% MACE, while non-carriers (n=35) had 38.89% refractory angina and 2.86% MACE; P > 0.9999 for refractory angina and P = 0.2744 for MACE, indicating no statistically significant association of CYP2C19*2 with recurrent ischemic events under a 150 mg/day maintenance dose.",
              "Sentence": "Genotypes CYP2C19*1/*2 + CYP2C19*2/*2 are not associated with response to clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*2 allele.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The allele frequencies were 8% for CYP2C19*2, 0% for CYP2C19*3, and 17% for CYP2C19*17. ... No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"As represented in Table [5], it was found that two patients (33.33%) from the CYP2C19*2 allele carrier group exhibited symptoms of refractory angina. However, this result did not demonstrate a statistically significant difference when compared with the non-carrier group, in which 14 patients (%38.89) exhibited similar symptoms (P > 0.9999).\"",
                "\"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Carriers of CYP2C19*17 had bleeding events in 16.67% (2/12) versus 6.9% (2/29) in non-carriers; Fisher\u2019s exact test P = 0.567, so the higher observed rate in carriers did not reach statistical significance under doubled maintenance dosing.",
              "Sentence": "Genotypes carrying the CYP2C19*17 allele are not associated with increased bleeding events of clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*17 allele.",
              "Alleles": "CYP2C19*1/*17 + CYP2C19*17/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "bleeding events of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*17",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The allele frequencies were 8% for CYP2C19*2, 0% for CYP2C19*3, and 17% for CYP2C19*17. ... No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table [7](#Tab7)).\"",
                "\"Among patients who underwent PCI and were treated with a double maintenance dose of clopidogrel, the carrier status of the CYP2C19*2 allele does not appear to be associated with an increased risk of MACE. ... Our study revealed a noteworthy observation regarding the incidence of bleeding events among the patients we investigated. Despite 30% of the individuals carrying the gain-of-function CYP2C19*17 allele and receiving a double maintenance dose of clopidogrel after stent placement, the occurrence of hemorrhagic events remained relatively low, not exceeding (9.7%).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Carriers of CYP2C19*17 had bleeding events in 16.67% (2/12) versus 6.9% (2/29) in non-carriers; Fisher\u2019s exact test P = 0.567, so the higher observed rate in carriers did not reach statistical significance under doubled maintenance dosing.",
              "Sentence": "Genotypes carrying the CYP2C19*17 allele are not associated with increased bleeding events of clopidogrel in patients with Disease:Coronary Artery Disease as compared to genotypes without the CYP2C19*17 allele.",
              "Alleles": "CYP2C19*1/*17 + CYP2C19*17/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "bleeding events of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*17",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The allele frequencies were 8% for CYP2C19*2, 0% for CYP2C19*3, and 17% for CYP2C19*17. ... No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.\"",
                "\"Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table [7](#Tab7)).\"",
                "\"Among patients who underwent PCI and were treated with a double maintenance dose of clopidogrel, the carrier status of the CYP2C19*2 allele does not appear to be associated with an increased risk of MACE. ... Our study revealed a noteworthy observation regarding the incidence of bleeding events among the patients we investigated. Despite 30% of the individuals carrying the gain-of-function CYP2C19*17 allele and receiving a double maintenance dose of clopidogrel after stent placement, the occurrence of hemorrhagic events remained relatively low, not exceeding (9.7%).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Bleeding events occurred in 33.33% (2/6) of CYP2C19*2 carriers versus 5.71% (2/35) of non-carriers; P = 0.0952, indicating a non-significant trend toward more bleeding among carriers under a double maintenance dose.",
              "Sentence": "Genotypes CYP2C19*1/*2 + CYP2C19*2/*2 are not associated with increased bleeding events of clopidogrel in patients with Disease:Coronary Artery Disease as compared to non-carriers of CYP2C19*2.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "bleeding events of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Our results indicated that carriers of the *CYP2C19*17* variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (*P* = 0.567; see Table [7](#Tab7)). Similarly, there was no statistically significant difference in bleeding events between *CYP2C19*2* carriers and non-carriers (*P* = 0.0952; see Table [7](#Tab7)), although a higher proportion of bleeding events was observed among carriers.\"",
                "\"Table 7 Caption: Distribution of bleeding events by CYP2C19 polymorphism\" and the corresponding data in Table 7: \"Allele CYP2C19*2 | Bleeding events ... Yes 2 (33.33%) | 4 (66.67%) ... No 2 (5.71%) | 33 (94.29%) | ... P value 0.0952\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Bleeding events occurred in 33.33% (2/6) of CYP2C19*2 carriers versus 5.71% (2/35) of non-carriers; P = 0.0952, indicating a non-significant trend toward more bleeding among carriers under a double maintenance dose.",
              "Sentence": "Genotypes CYP2C19*1/*2 + CYP2C19*2/*2 are not associated with increased bleeding events of clopidogrel in patients with Disease:Coronary Artery Disease as compared to non-carriers of CYP2C19*2.",
              "Alleles": "CYP2C19*1/*2 + CYP2C19*2/*2",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "bleeding events of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Coronary Artery Disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of CYP2C19*2",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Our results indicated that carriers of the *CYP2C19*17* variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (*P* = 0.567; see Table [7](#Tab7)). Similarly, there was no statistically significant difference in bleeding events between *CYP2C19*2* carriers and non-carriers (*P* = 0.0952; see Table [7](#Tab7)), although a higher proportion of bleeding events was observed among carriers.\"",
                "\"Table 7 Caption: Distribution of bleeding events by CYP2C19 polymorphism\" and the corresponding data in Table 7: \"Allele CYP2C19*2 | Bleeding events ... Yes 2 (33.33%) | 4 (66.67%) ... No 2 (5.71%) | 33 (94.29%) | ... P value 0.0952\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.37382937636640334,
      "total_samples": 6,
      "ground_truth_annotations": {
        "count": 6,
        "matched_count": 3,
        "unmatched_count": 3,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8686833798885345,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*2 + *2/*2 + *2/*17",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Major Adverse Cardiac Events (MACE)",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                "prediction": "*2",
                "score": 0.9324532747268677,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                "prediction": "Efficacy:Refractory angina symptoms, Efficacy:Major adverse cardiac events",
                "score": 0.9150474667549133,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers",
                "score": 0.8393330574035645,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7730735838413239,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Hemorrhage",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "*1/*17 + *17/*17 + *2/*17",
                "prediction": "*2",
                "score": 0.9201368689537048,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hemorrhage",
                "prediction": "Side Effect:Bleeding events",
                "score": 0.9712659120559692,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers",
                "score": 0.8393330574035645,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6746380388736725,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Hemorrhage",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*17",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "*1/*17 + *17/*17 + *2/*17",
                "prediction": "*17",
                "score": 0.9357814192771912,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hemorrhage",
                "prediction": "Side Effect:Bleeding events",
                "score": 0.9712659120559692,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers",
                "score": 0.8393330574035645,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1454052100,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Among patients who underwent PCI and were treated with a double maintenance dose of clopidogrel, the carrier status of the CYP2C19*2 allele does not appear to be associated with an increased risk of MACE.\" \"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744).",
              "Sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
              "Alleles": "*1/*2 + *2/*2 + *2/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Major Adverse Cardiac Events (MACE)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40295977",
              "Variant Annotation ID_norm": "1454052100",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1454052160,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P = 0.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.",
              "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Hemorrhage",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40295977",
              "Variant Annotation ID_norm": "1454052160",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1454052160,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40295977,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P = 0.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.",
              "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
              "Alleles": "*1/*17 + *17/*17 + *2/*17",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:Hemorrhage",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40295977",
              "Variant Annotation ID_norm": "1454052160",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7307251274585724,
      "total_samples": 2,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 2,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6448371901231653,
            "annotation": {
              "Study Parameters ID": 1454052120,
              "Variant Annotation ID": 1454052100,
              "Study Type": null,
              "Study Cases": 41.0,
              "Study Controls": null,
              "Characteristics": "MACE, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.08,
              "Allele Of Frequency In Cases": "*2",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.2744",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Near Eastern"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454052120,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052100,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "prospective",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 41.0,
                "prediction": 41,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "MACE, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                "prediction": "Syrian coronary artery disease patients undergoing PCI on dual antiplatelet therapy including doubled maintenance dose clopidogrel 150 mg/day; comparison of CYP2C19*2 allele carriers vs non-carriers for major adverse cardiac events (MACE)",
                "score": 0.962232232093811,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": 0.08,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*2",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.2744",
                "prediction": "= 0.2744",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6446777406860801,
            "annotation": {
              "Study Parameters ID": 1454052180,
              "Variant Annotation ID": 1454052160,
              "Study Type": null,
              "Study Cases": 41.0,
              "Study Controls": null,
              "Characteristics": "Bleeding events, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.17,
              "Allele Of Frequency In Cases": "*17",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.567",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Near Eastern"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454052180,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052160,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "prospective",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 41.0,
                "prediction": 41,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Bleeding events, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                "prediction": "Syrian coronary artery disease patients undergoing PCI on dual antiplatelet therapy including doubled maintenance dose clopidogrel 150 mg/day; comparison of CYP2C19*17 allele carriers vs non-carriers for bleeding events",
                "score": 0.9595215916633606,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": 0.17,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*17",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.567",
                "prediction": "= 0.567",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 2,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "prospective",
              "Study Cases": 41,
              "Study Controls": null,
              "Characteristics": "Syrian coronary artery disease patients undergoing PCI on dual antiplatelet therapy including doubled maintenance dose clopidogrel 150 mg/day; comparison of CYP2C19*2 allele carriers vs non-carriers for refractory angina symptoms",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.9999",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Near Eastern",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "prospective",
              "Study Cases": 41,
              "Study Controls": null,
              "Characteristics": "Syrian coronary artery disease patients undergoing PCI on dual antiplatelet therapy including doubled maintenance dose clopidogrel 150 mg/day; comparison of CYP2C19*2 allele carriers vs non-carriers for bleeding events",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.0952",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Near Eastern",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}